Salix licenses S1P receptor modulator from Mitsubishi

Mitsubishi has found a new partner for its oral S1P receptor modulator in Salix, two years after Biogen decided to return its rights to the compound.

Salix Pharmaceuticals Ltd. gained exclusive rights Thursday to develop and commercialize amiselimod (MT-1303) worldwide, excluding Japan and other Asian territories. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) receives an undisclosed upfront payment, and is eligible for development and regulatory milestones, plus royalties...